Search

Displaying results 5371 - 5380 of 10000 in total
  1. Drug

    Trichophyton tonsurans

    go.drugbank.com/drugs/DB10970
    Approved

    Trichophyton tonsurans is a fungus which can provoke allergic reactions. Trichophyton tonsurans extract is used in allergenic testing.

  2. Drug

    Trichophyton verrucosum

    go.drugbank.com/drugs/DB11295
    Approved

    Trichophyton verrucosum is a fungus which can provoke allergic reactions. Trichophyton verrucosum extract is used in allergenic testing.

  3. Drug

    Lucitanib

    go.drugbank.com/drugs/DB11845
    Investigational

    Lucitanib has been used in trials studying the treatment of ER+, MBC, SCLC, HER2+, and NSCLC, among others.

  4. Drug

    TCB-008

    go.drugbank.com/drugs/DB18352
    Investigational

    TCB-008 is an Allogeneic CD3+ T lymphocyte ex vivo expanded expressing the gamma delta T-cell receptor.

  5. Drug

    Dihydrocapsiate

    go.drugbank.com/drugs/DB15398
    Investigational

    Dihydrocapsiate is under investigation in clinical trial NCT00999297 (Effect of 4-week Dihydrocapsiate Ingestion on Resting Metabolic Rate).

  6. Drug

    Palmitic Acid

    go.drugbank.com/drugs/DB03796
    ApprovedInvestigational

    A common saturated fatty acid found in fats and waxes including olive oil, palm oil, and body lipids.

    Mixtures: Huile D'onagre Vitamin E
  7. Drug

    Acriflavine

    go.drugbank.com/drugs/DB13373
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Nizofenone

    go.drugbank.com/drugs/DB13546
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Branaplam

    go.drugbank.com/drugs/DB14918
    Investigational

    Branaplam is under investigation in clinical trial NCT02268552 (An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)).

  10. Drug

    Firtecan pegol

    go.drugbank.com/drugs/DB14953
    Investigational

    Firtecan pegol is under investigation in clinical trial NCT01036113 (A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer).